Therefore, the present real-world study evaluated the treatment patterns and survival outcomes of abemaciclib in patients with HR+/HER2- locally advanced or mBC in two Middle Eastern countries, Kuwait and Lebanon, which have one of the highest incidences of BC in the region (21, 22). The gene discussed is ERBB2; the disease is breast cancer.